NCT00894894 2024-08-02Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid MalignanciesAstex Pharmaceuticals, Inc.Phase 1 Completed22 enrolled
NCT00504205 2013-08-02MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or LymphomaNational Cancer Institute (NCI)Phase NA Terminated30 enrolled